We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Onward

News List

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier prnasia
June 08, 2021
Onward Therapeutics (Onward) and Institut du Cancer de Montpellier (ICM) announced today the execution of an exclusive collaboration and worldwide option and license agreement based on a research program in onco-metabolism being conducted by ICM ...
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy prnasia
February 22, 2021
Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
Biomunex, Onward Ink Strategic Antibody Development Pact contractpharma
February 18, 2021
Exclusive worldwide license and development agreement will leverage Biomunex' next gen bi- and multi-specific antibody platform in hematological malignancies.